Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Venetoclax plus azacitidine are effective in treating newly diagnosed AML in patients who
cannot recieve intensive chemotherapy. However there is no clinical data rewarding the
efficacy and safety of low-dose venetoclax and azacitidine as first-line therapy.